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Abtract
Most of drugs are metabolized by cytochrome P 450 (CYP) enzyme. Cytochrome P450 3A4 is the 
cytochrome that is involved in metabolizing more than 60% of all medicine used in human. The variation 
of this CYP3A4 gene will affect the catalytic activity of this enzyme. Recently, CYP3A4*1G in intron 10 was 
found  in Chinese and Japanese population. There  is a substitution of G to A at position 82266 in intron 10. The 
purpose of this research was to investigate the frequency of allele and genotype CYP3A4*1G. Samples were 
taken from bloods of the subjects of the research. The examination of CYP3A4*1G was conducted by RTLP-PCR 
method.As the results of this research, the frequency of CYP3A4*1G in Javanese people is CYP3A4*1/*1 0.25, 
CYP3A4*1/*1G 0.55 and CYP3A4*1G/*1G 0.20. Frequency of allele G: 0.53, allele A: 0.47. The Fisher’s exact- test 
shows that the allele and genotype frequencyis p. 1.000. The allele and genotype frequency of Javanese people 
isstill in Hardy-Weinberg equilibrium.
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Introduction
The response to drugs delivery is 
influenced by many factors. These factors 
included drug’s factors and host factors. 
Host factors that affect clinical response 
are age, nutritional status, and physiologic 
organs including genetics factors. Genetic 
variation that currently focused on attention 
is genetic polymorphism in individual that 
leads to differences in treatment response. 
Polymorphism in individual can influence the 
pharmacokinetic profile of drugs, including 
absorption, distribution, metabolism and 
elimination. This happens because these 
polymorphism can cause level of drugs 
does not achieve the expected therapeutic 
levels (sub therapeutics), or even cause toxic 
therapeutics. Sub therapeutic levels can cause 
the treatment failure and toxic therapeutics 
level can lead to excessive drugs effect 
(Alvirevi et al, 2006)
CYP3A4 enzyme is present in liver 
and gastrointestinal tract (Tomaszewski et 
al., 2008; Hsieh, et al., 2001) and inrenal dan 
prostatparencim (Tomaszewski et al., 2008). 
Human liver caontains the most abundant 
isoenzyme of CYP450 (Gao et al., 2008). It has 
18 isoform numbers with a molecular weight 
of 57,1kD (Tomaszewski et al., 2008). CYP3A4 
is involved in the metabolism of more than 
50% of drugs in human (Van Schaik et al., 
2000 ; Wang et al., 2005), among of these 
are alprazolam, amiodaron, amlodipin, 
amitriptilin, atorvastatin, deksametason, 
dektrometorpan, diazepam, digoksin, 
diltiasem, ketokonazole, ondansentron, 
terfenadin, progesterone, nateglinid and 
others (Tomaszewski et al., 2008).
*Corresponding Author:
Em Sutrisna
Faculty of Pharmacy, Muhammadiyah University of 
Surakarta, Jl. A.Yani Tromol Pos 1 Pabelan, Surakarta, 
Indonesia 
E-mail: em_sutrisna@yahoo.com
I.J. Biotech.
84
Sutrisna et al.
Polymorphism can be found on 
the enzyme of drugs metabolism gene, 
drugs traport gene, and drugs target gene. 
Polymorphism that is most widely mapping 
is on drug metabolism gene. Most of drugs 
are metabolized by cytochrome P450 (CYP). 
From the various CYP that has been mapped, 
CYP3A4 metabolizes more than 60% of 
medicines given to human. The research 
on the Malaysia’s population showed that 
there were 2,1% CYP3A4*18 (Ruzilawati 
et al., 2007). Mapping of the CYP3A4*1G 
polymorphism has not been done in Indonesia 
and Malaysia.
The purpose of this research is to 
investigate the allele and genotype frequency 
of CYP3A4*1G on Javanese people.
Materials and Methods
Subjects
The Javanese people patients that took 
cure in Balai Kesehatan Paru Masyarakat 
(BKPM) Klaten and Balai Kesehatan Paru 
Masyarakat (BKPM) Yogyakarta. Inclusion 
criteria were age>14 years, Javanese ethnic 
(three generation and over) while exclusion 
criteria was family relationships (father, 
mother, grandmother, grandfather, children 
and grandchildren).
DNA isolation
DNA isolation was performed by 
using Wizard®genomic DNA purification 
kit Promega, which steps were done as 
refered to manufacture recommendation. 
Briefly, 100 µL of cell lysis solution was 
added in 300 µL of buffy coat samples were 
incubated 10 min. On room temperature, 
mix solutions were centrifuged 13.000 for 1 
min. After supernatant was discarded, 300 
uL of solution was added on the residue. 
The mixture was vortexed 10-15 sec. The 
result of the mixture was added by 1,5 mL 
of RNA solution, then was vortexed 10-15 
sec. These mixtures were incubated on 370C 
then stored in room temperature and added 
by 100 µL of protein presipitation solution. 
Mixture then was vortexed on 10-15 sec and 
centrifuged 13.000 for 3 min on 370C. Three 
hundreds µL of  supernatant was taken and 
put into 1,5 mL tube then added by 300 µL 
isopropanol. The solution was mixed by 
inversion until the white treads-like strands 
of DNA form a visible mass, then centrifuged 
on 13.000 for 1 min at 370C. The supernatant 
was discarded and the residue was added 
by 300 uL of 70% ethanol. It was mixed a 
few time and centrifuged on 13.000 for 1 
min on 370C. The ethanol was removed after 
inversion. The residue was added by DNA 
rehydration solution (100 µL for 300 µL 
sample volume) and incubated at 650C for 
60 min. Periodically, the solution is mixed by 
gently tapping the tube. The samples were 
stored at 40C.
Polymerase chain reaction CYP3A4*1G
A total of 12,5mL master mix , 6,5 mL 
dH2O, forward 5’- CAC CCT GAT GTC CAG 
CAG AAA CT-3’ dan 2µL reverse 5’-AAT AGA 
AAG CAG ATG AAC CAG AGCC-3’ and 2µL 
DNA (25µL total) were mixed and run by PCR. 
Amplification conditions as follows: 940 C for 
7 min, the 35 cycles by 30 secs on  940C, 1 min 
on 620C, dan 1 minon 720C with 5 min final 
extensionat 720C. After PCR amplification, 8 
µL of PCR products of 287 bp was digested by 
10 U RsaI for 12 h at 370C. The digested PCR 
products were analyzed by electrophoresis 
on 2% agarose gel and detected by ethidium 
bromide. The bands of DNA fragments were 
visualized by UV light (Gao et al., 2008)
Figure 1. Electrophoregram of amplification products 
of CYP3A4 
I.J. Biotech.
85
Sutrisna et al.
Results
A total 60 subjects whom fulfilled the 
inclusion and exclusion criteria were used 
as test subjects.
The sample material was derived 
from blood buffy coat. The DNA purity 
was measured from ratio of absorbance 
at A260/280. The results of these samples 
were 1,7-2. DNA concentration was 50µg/
mL with dilution. DNA which had isolated 
then amplified by RFLP- PCR. Results can be 
seen in Figure 1.
The digested RFLP-PCR-products that 
analyzed by 2% agarose gel electrophoresis 
is shown on Figure2.
Figure 2 shows that lanes 3,4,8, and 9 
contained digested product of RFLP-PCR 
with size 287 bp, 217 bp and 70 bp. These 
are CYP3A4*1/*1G (heterozygote variant 
type). Lane 5 (287bp) was not digested. 
This is homozygote variant/mutant type 
(CYP3A4*1G/*1G). The lane 6 and 7 shows 
digested product of 217 bp and 70 bp (wild 
type CYP3A4*1/*1).
The genotype and allele frequency can 
be seen in Table 1 and 2.
Table 2 showed that the sum of 
frequency of (G)+frequency (A)=1, and 
nG2 + 2nGnA + nA2=1. The frequency of 
genotype and allele was not deviated from 
Table 2. Frequency of genotype& allele on subject test
Subjects Frequency 
of  genotype
Frequency 
of  allele
P value
CYP3A4*1G
CYP3A4*1/*1- 14(23.3%)
CYP3A4*1/*1G- 34 (56.7%)
CYP3A4*1G/*1G- 12 (20%)
Allel G (*1)- 0.52
Allel A (*1G)- 0.48
1.000*
*test was done by Fisher’s exact- test
Table 3. Frequency genotype and allele of CYP3A4*1G from the others populations:
Populations frequency allele frequency genotype RefG (*1) A(*1G) *1/*1 *1/*1G *1G/*1G
Javanese 0.53 0.47 0.25 0.55 0.20 This study
China 0.724 0.276 0.51 0.43 0.06 Gao et al., 2008
China 0.75 0.25 0.58 0.34 0.08 Dong et al., 2011
Figure 2.Detection of polymorphism in CYP3A4 *1G 
using PCR-RLFP. Lane 1 is marker 100bp, lane2. 
Uncut; lane 3,4,8,9 are from samples of CYP3A4 *1/*1G 
(heterozygotes); lane  5 is CYP3A4 *1G/*1G (mutant/
variant type homozygotes) and lane 6-7 are samples of 
CYP3A4 *1/*1 (Wild type)
Table 1. Characteristic of subject test based on sex
gene Sex totalMale Female
CYP3A4*1/1 6 8 14
CYP3A4*1/1G 20 14 34
CYP3A4*1G/1G 6 6 12
total 32 28 60
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Hardy-Weinberg equilibrium on p. 1,000. The 
comparison of this study with research in 
Chinese population can be seen in Table 3. 
Discussion
The result of this study showed that the 
frequency of polymorphism of CYP3A4*1/*1 
was 0,25, CYP3A4*1/*1G was 0,55 and 
CYP3A4*1G/*1G was 0,20. Frequency of allele 
G was 0,53, while the frequency of allele A was 
0,47. By comparing to two studies on Chinese 
populations, it showed that the frequency of 
variant type/mutant type  CYP3A4*1G/*1G 
of Javanese population is much higher than 
Chinese population. The result of the genetics 
findings is diferent from anthropological 
studies. Anthropological studies states that 
the island of Java had inhabited by Homo 
sapiens since 40,000 years ago. The earliest 
inhabitants were austromelanesid ethnic that 
since 10.000 years ago were mongolidizied. 
This process became more intensive during 
last 1000 years. The Javanese were formed 
since 2168 years ago (Glinka, 2006), so there 
is a relationship between Mongolian and 
Javanese ethnics. The frequency of mutant/
variant type in this research is relatively large 
(55% in heterozygotes and 20 % homozygous 
of CYP3A4*1G/*1G).
CYP3A4*1G was determined by the 
substitution of 82266 G>A. Location of this 
variant is in intron 10 of the CYP3A4 gene. 
It was resulted in the change of amino 
acid from isoleusin into valin (I369V). 
Both of these amino acids have different 
polarity levels and molecular weight. The 
molecular weight of isoleucine (C6H13NO2) 
is 131.1736g/mol, while molecular weight of 
valine (C5H11NO2) is 117.1469g/mol. The 
amino acid with different unit’s nature will 
reduce the catalyzing ability of cytochrome 
enzyme (CYP3A4) (Gao et al., 2008). Thus, 
the effects of CYP3A4*1G polymorphism 
is vary. After atorvastatin given, the mean 
percent reduction of total cholesterol 
plasma in individual with CYP3A4*1/*1 is 
16,83±3%, 17,8±3,8 % (*1/*1G) and 20,9±5,0% 
(*1G/*1G).Conversely, a decreasing in 
total cholesterol on simvastatin therapy 
showed no difference among these three 
variants (Gao et al, 2008). Yuan et al (2011) 
states that individual with variation of 
CYP3A4*1G/*1G has a lower metabolic 
rate of fentanyl than type CYP3A4*1/*1G 
and CYP3A4*1/*1. The fentanyl plasma 
levels of individual with CYP3A4*1/*1 (12,8 
±6,5 ng/mL) was significantly lower than 
CYP3A4*1/*1G (16,8± 9,0 ng/mL, p<0,01) 
and lower than individual with variant type 
CYP3A4*1G/*1G ( 28,1±9,5 ng/mL, p<0,01) 
(Yuan et al., 2011). Variation effect of this 
polymorphism could occured because of 
the substitution of guanine by adenine that 
occured at 82266 (G82266A) in variant type 
CYP3A4*1G/*1G, which causes a change 
from isoleucine to valine (I 369 V) (Gao et 
al., 2008). This amino acid change would 
reduce the ability of catalyzing cytochrome 
(CYP3A4) which may causes plasma drugs 
levels becoming higher. Therapy of drugs 
which are substrates of CYP3A4 together 
with other drugs, which both are inductor 
and inhibitors of CYP3A4, should also be 
tested to predict its effects.
Based on this result, therapy of drugs 
which are substrates of CYP3A4 must be 
carried carefully. Several drugs had been 
known as inhibitors and inductors. The 
drugs known as inductors CYP3A4 such 
as antiepileptic drugs (classphenobarbital, 
phenytoin, carbamazepine, felbamate, 
lamotrigine, oxcarbazepine, primidone, 
rufinamid & topiramate), cyclophospamid, 
dexamethason, erythromisin, griseofulvin, 
lansoprazole ,nevirapin,  omeprazol , 
pioglitasone, prednisone, rifampin,troglitason.
The drugs known as inhibitor of CYP3A4 are 
chlorampenicol, cimetidin, cyprofloxasin, 
flukonazole, itrakonazole, nevirapin, 
norfloxasin, varikonazole, mibefradile, 
estradioleand (Tomaszewski et al., 2008). 
Therapy of drugs which are substrates of 
CYP3A4 together with its inhibitor may 
increase drugs plasma level. This can cause 
adverse effect. Conversely, the therapy of drugs 
that are substrates of CYP3A4 together with its 
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inductor may decrease drugs plasma level and 
can cause failure of the treatment. 
As the conclusion, the frequency of 
CYP3A4*1G in Javanese people were 0,25 for 
CYP3A4*1/*1, 0,55 for CYP3A4*1/*1G, and 
0,20 for CYP3A4*1G/*1G. Frequency of allele 
G was 0,53 while allele A was 0,47. Allele and 
genotype frequency of Javanese people  were 
still in Hardy-Weinberg equilibrium.
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